Implantation of the Micra transcatheter pacing system: A single center North India experience

Viveka Kumar a, Rajendra Agarwal b, Mitendra Singh Yadav c, Sangeeta Dhir d,*, Vivek Kumar c

a Director, Cath Labs, Department of Cardiology, Max Superspeciality Hospital, New Delhi, India
b DNB Interventional Cardiology, Department of Cardiology Max Superspeciality Hospital, New Delhi, India
c Department of Cardiology, Max Superspeciality Hospital, New Delhi, India
d MDS Periodontology, Fellow Implantology Department of Cardiology, Max Superspeciality Hospital, New Delhi, India

Article info
Article history:
Received 6 June 2020
Received in revised form
20 August 2020
Accepted 21 October 2020
Available online 17 November 2020

Keywords:
Leadless pacemaker
Micra transcatheter pacing system
Leadless pacing system, cardiac pacing
Brady cardiac
Micra TPS

Abstract
Background: The leadless pacemaking transcatheter system, Micra, is a miniaturized, single-chamber pacemaker system. We report herein our experience with implantation of the Micra TPS system.
Objective: The current study was conducted to evaluate the safety and efficacy of the leadless Micra Transcatheter Pacemaker System (Medtronic).
Research design and methods: This was a prospective single centre nonrandomized study without controls. A transcatheter pacemaker was implanted in patients who had guideline based indications for ventricular pacing. 28 subjects were screened based on the selection criteria. Mica TPS was implanted. Parameters assessed were: duration of procedure (from femoral vein puncture to venous access closure), fluoroscopy time, number of device repositions, periprocedural electrical measurements (sensing, threshold and impedance) and in-hospital, intermediate to long term adverse events related to procedure.
Result and conclusion: The device was successfully implanted in 28 subjects. The mean intraoperative sensing value was 9.04 ± 1.5 mV and the impedance was 766.89 ± 213.9 Ω. At discharge from hospital, those values were 13.2 ± 15.83 mV and 855 ± 111.7, respectively. The recommended pacing threshold value as achieved in all subjects was 0.78 V, i.e. /C20 1 V at 0.24 ms. There was no adverse event or complications reported for any of the subjects. Mean time from hospitalization to discharge was 1.5 days. Implantation of leadless pacemakers is feasible, safe and provides advantages over the conventional system.

1. Background
Cardiac pacemakers are implanted, in approximately over a million of patients every year [1]. The number of patients globally undergoing pacemaker implantation has increased steadily up [2]. The first epicardial pacing system was implanted almost 50 years ago. Ever since significant advancements in pacemaker technology has undertaken, thereby evolving of highly sophisticated, transvenous pacing systems. These high-performance devices undoubtedly contributed to the improvement of both prognosis and the quality of life of patients with bradyarrhythmias resulting from Sick Sinus Syndrome and high degree atrioventricular (AV) block [3,4]. Improvisation in the technological achievements in the field of pacing, in relation to longevity of battery and miniaturization of the device, software programme, lead performance, implantation techniques have evolved pacing as an option that is safe and reliable.

1.1. Complications of traditional pacemakers

Conventional pacemakers are associated with a significant risk of complications. Short term transvenous pacemaker-related complication rates have been reported in 9.5%—12.6% of patients [5]. Complications are related to the pocket or lead. Frequently

https://doi.org/10.1016/j.ipej.2020.10.005
0972-6292/Copyright © 2020, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
encountered are the lead related problems which include pneumothorax, cardiac perforation, lead dislodgement, venous thrombosis, obstruction of branches of superior cava, regurgitation of the tricuspid valve and infections. Pocket-related complications include hematomas, skin erosion, or life-threatening pocket infections requiring extraction of the pacemaker systems [6,7]. Studies have shown that long-term complications are primarily related to lead failure, identifying it as the weakest component of the current pacing system [5,6]. Early recognition of these complications triggered the researchers to conceptualize the leadless pacemaker system in the 1970’s and successfully implanted in dogs using a mercury battery powered capsule [8]. Ever since there has been gradual development in the technology. In 2016 CE and FDA approved single-chamber right ventricular leadless cardiac pacemaker was introduced as Micra Transcatheter Pacing System (TPS; Medtronic).

1.2. Advancements in pacing technology

1) advances in component design including miniaturization and low power utilization advancements, (2) improvements in battery technology to allow adequate pacemaker longevity despite its low profile and overall size, (3) communication protocols to also minimize power utilization, 4) practical catheter-based delivery tools to negotiate the vasculature and cardiac anatomy and permit safe affixation to the myocardial wall.

1.3. Micra TPS characteristics

Table 1 depicts characteristics of Micra Pacing system [9,10,23,24]. (Fig. 1) The cathode is steroid eluting to reduce inflammation, and situated on the distal end of the pacemaker. The device is fixated by nitinol tines. The unique feature of nitinol tine design is to pulls the micra cathode into contact and constantly seeks to return to its original form.

1.4. Objective of the study

This is a prospective non randomized without control single centre study presenting an early experience with Micra leadless pacemaker placement.

2. Research Design and methods

The study was conducted in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Ethics approval was obtained from the Institutional Ethical Committee at Max Super Specialty Hospital, New Delhi, India. Based on the selection criteria subjects were enrolled for the study.

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| individual ≥ 18 years of age | pacemaker syndrome |
| chronic and/or permanent atrial fibrillation associated with complete heart block | retrograde ventriculoarterial (VA) conduction |
| sick sinus syndrome (SSS) complete heart block (CHB) | drop in arterial blood pressure with the onset of ventricular pacing |
| ECG findings suggestive of significant conditions and disorder | pre-existing endocardial defibrillation with current implantation of: either conventional or subcutaneous implantable cardioverter defibrillator or cardiac resynchronization therapy |
| evidence of thrombosis in one of the veins used for access during the procedure | implanted vena cava filter |
| previous implanted leadless cardiac pacemaker | Cardiovascular or peripheral vascular surgery within 30 days of enrolment |

28 subjects were enrolled for this study. Written informed consent, briefing the characteristics of the new system indications and potential complications, was obtained prior from the enrolled subjects Parameters assessed were: duration of procedure (from femoral vein puncture to venous access closure), fluoroscopy time, number of device repositions, peri procedural electrical measurements (sensing, threshold and impedance) and in-hospital, intermediate to long term adverse events related to procedure. Post implantation of the device subject underwent chest radiography
and standard ECG before hospital discharge. Follow-up assessments were done at 1 week, 1-3-6 months up to 3 years.

2.2. Device implantation

The Micra TPS is a single chamber ventricular pacemaker. The device was attached to a steerable catheter delivery system with catheter and inserted through a femoral vein with the use of a 23-French (outer diameter 27 F) introducer sheath. The delivery system was advanced into the right ventricle (RV), and the device was affixed to the myocardium with four electrically inactive nitinol tines located at the distal end of the device (Fig. 2). The optimal electrical measurement results were checked. In the event the electric measurement are not achieved, the system is fully repositionable while the device is still connected to the delivery system. The optimal location of device placement in the right ventricle was determined by injecting radiographic contrast. After electrical threshold testing and determining stability with a positive tug test, the device was released from the delivery system (Fig. 3, Fig. 4, Fig. 5). Vascular access site was closed with subcutaneous absorbable double ‘figure-of-eight’ suture followed by 4 h bandage compression used for the access site in the groin [11].

3. Results

Micra pacemaker was implanted in 28 subjects. The device were implanted through the femoral vein to the right ventricle septum. The mean age group of the subjects was 71.71 ± 8.44 years, 20 males (71%) 8 females (28%). Pacemaker indications included: Atrial Fibrillation (50%), complete heart block (25%), bradycardia syndrome (7%), sinus arrest with infrequent pauses or syncope (7%), sick sinus syndrome & Morgagni Adams Stokes Syndrome (35.71%), Sick sinus syndrome (35%). Concomitant comorbidities were diabetes mellitus (39.28%) coronary artery disease (46.4%), hypertension (78.5%) chronic kidney disease (17.8%) COPD (7.1%) (Table 2). 8 subjects had infections related to the previous placement of conventional pacemakers. Mean procedure time was 1.05 ± 0.07 h. Mean fluoroscopy duration was 3.29 ± 5.34 min.

(minimum 3’11’’- maximum 5’11’’). Repositioning of the system and the position of the device was changed 14 patients, among them 10 patients underwent 1 time only while 2 times only in 4 subjects due to suboptimal pacing threshold or sensing value. The mean intraoperative sensing value was 9.04 ± 1.5 mV and the
impedance was 766.89 ± 213.9 Ω. At discharge from hospital, those values were 13.2 ± 15.83 mV and 855 ± 111.7 mV, respectively. The recommended pacing threshold value as achieved in all subjects was 0.78 V, i.e. 1 V at 0.24 ms. There was no adverse event or complications reported for any of the subjects. Mean time from hospitalization to discharge was 1.5 days (Table 2). Subjects were followed up to 3 years.

4. Discussion

Introduction of leadless pacemakers have presented advantages over conventional transvenous systems. Predominant complications are related to lead and pocket in transvenous cardiac pacing system [12]. Pacing leads and the pacemaker serve as a potential foreign body source for infections [13]. The small size, reduced surface area, and lack of lead exposed to the bloodstream appear to substantially mitigate the risk of early device infection in Micra pacemakers. Micra implantations have reported high procedural success rate of varying results: 97% [14], 95.8% [15], 99.2% success rate was reported in a full cohort of 719 patients. 6 months of follow-up, efficacy and safety of the device were evaluated against performance goals that were based on data from recipients of conventional transvenous pacemakers study [16]. A recent report from the Micra study compared matched cohorts of transvenous pacemakers, demonstrating 48% lower complications and 47% less hospitalizations at one year, driven by an 82% decrease in pacemaker revision procedures in the Micra group [17]. The interim report from Micra TPS post-approval registry also showed high procedural efficacy with 99.6% successful implantations [18]. In our study the pacing devices were successfully implanted in all 28 subjects to the RV Septum confirmed by the LAO projection with contrast medium injection. The septal positioning of the pacemaker system have been reported with benefits in terms of avoiding pericardial effusion and tamponade. In the literature a trend toward

Table 2
Baseline characteristics of the subjects.

| Characteristics | Mean ± SD | N (%) |
|-----------------|-----------|-------|
| Gender          |           |       |
| Male            |           | 20 (71)|
| Female          |           | 8 (28) |
| Age (Years)     | 71.71 ± 8.4|       |
| Comorbidity     |           |       |
| CAD             |           | 7 (39.28)|
| Diabetes        |           | 12 (65.40)|
| Hypertension    |           | 19 (78.5)|
| CKD             |           | 4 (17.8)|
| COPD            |           | 2 (7.1)|
| LVEF            |           | 52.85 ± 4.17| |
| Indication for Pacemaker – Micra | | |
| AV block 2      |           | 7 (25.0)|
| SA with syncope |           | 3 (10.7)|
| Bradytachy Syndrome |       | 2 (7.0)|
| SSS-MASS        |           | 10 (35.7)|
| AV block 3      |           | 6 (21.4)|
| Average number of days in hospital | 1.5 days (hospitalization to discharge) | |
| Contraindication for traditional pacemaker | | |
| Post PPI + PI   |           | 8 (28.5)|
| Bilateral lymphoedema |       | 2 (7.1)|
| AV Fistula thrombosis |       | 2 (7.1)|
| NONE            |           | 16 (57.1)|
| Basal Rhythm    |           |       |
| AF              |           | 8 (28.5)|
| NSR paroxysmal AF |       | 14 (50.0)|
| NSR             |           | 6 (21.4)|

CAD – coronary artery disease, AF – atrial fibrillation, LVEF – left ventricular ejection fraction, CHB- complete heart block, SA – sinus arrest, SSS – sick sinus syndrome, MAS – morgagni adams stokes syndrome, COPD – chronic obstructive pulmonary disease, CKD – chronic kidney disease, AV – atrioventricular, NSR – normal sinus rhythm, PI – pocket infection, PPI – permanent pacemaker implantation.
more frequent septal implantations could be observed. 65.9% apical implantations in one of study compared to 39.3% in post-approval registry [19,20]. The electric parameters were maintained in all the subjects above the defined thresholds of the sensing values during the procedure and time of discharge. This is in accordance with the previous published studies [20–22]. In comparison to the traditional pacing systems, few procedural and long-term complications are reduced with leadless pacemaker but it also brings new problems i.e. vascular complications at the groin puncture site. In the IDE study arteriovenous fistula or pseudoaneurysm occurred in 5 (0.7%) patients [19]. A similar rate of vascular complications was observed in post-approval registry. Among total 0.75% of access site complications, there were 2 hematomas (0.25% of patients) [20]. The possible complications with Micra are: cardiac perforation, cardiac tamponade, large haematoma needing blood transfusion, Micra embolization. None of these complications were reported in our study during the sequence of followups.

5. Conclusion

This study was carried out at a single cardiology centre. It showed that the leadless cardiac pacemaker was capable of providing effective and safe pacemaker function in a varied group of patients who had indications for long-term pacing therapy. Leadless pacemakers have shown both safety and efficacy in the short term and long term follow-up (3 years) as an alternative to transvenous pacemakers. Our study suggests multicentre randomised controlled clinical trials of Micra TPS with long term follow up.

CRediT authorship contribution statement

Viveka Kumar: Conceptualization, Methodology, Investigation, Supervision, Formal analysis, Validation, Resources. Rajendra Agarwal: Methodology, Investigation, Validation, Writing - review & editing. Mitendra Singh Yadav: Investigation, Project administration. Sanjeeta Dhir: Writing - original draft, Writing - review & editing. Vivek Kumar: Supervision, Writing - original draft.

References

[1] Mond HG, Proclerem A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009-a World Society of Arrhythmia’s project. Pacing Clin Electrophysiol 2011;34:1013–27. https://doi.org/10.1111/j.1540-8159.2011.03150.x.
[2] Raatikainen MJ, Arnard DO, Zeppenfeld K, et al. Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association. Europace 2015;17(Suppl 1):11–75. https://doi.org/10.1093/europace/eu5300.
[3] Brigide M, Arricchio A, Baron-Esquivias G, et al. ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15(8). https://doi.org/10.1093/europace/eut060, 1070–18.
[4] Kusumoto FM, Schoenhfeld MH, Barrett C, et al. ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay. A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol 2019;109(24):
[5] Kufkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014;35(18):1186–94. https://doi.org/10.1093/eurheartj/ehu147.
[6] Hudo ED, Zuthoff NP, van Herner NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm 2012;9(5):728–35. https://doi.org/10.1016/j.hrthm.2011.12.014.
[7] Tarjki KG, Wazni OM, Harb S, et al. Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of vegetation on survival, EP Europace 2014;16(10):1496–5. https://doi.org/10.1093/europace/euu147.
[8] Spicler JW, Rasor NS, Kezdi P, et al. Totally self-contained intracardiac pacemaker. J Electrocardiol;3(3–4):325–331. DOI: 10.1016/s0022-0736(70)80059-0.
[9] Miller MA, Neuzil P, Dukkipati SR, Reddy VY. Leadless cardiac pacemakers: back to the future. J Am Cardiol 2015;66;11791e1189.
[10] Sperzel J, Burri H, Gras D, et al. State of the art of leadless pacing. State of the art of leadless pacing. Europace2015;17:1508–1513. DOI: 10.1093/europace/eu1496.
[11] El-Chami MF, Roberts PR, Kypta A, et al. How to implant a leadless pacemaker with a tine-based fixation. J Cardiovasc Electrophysiol 2016;27(12). https://doi.org/10.1111/jce.13092. 1495–91.
[12] Kufkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014;35:1186–94. https://doi.org/10.1093/eurheartj/ehu147.
[13] Tarajki KG, Wazni OM, Harb S, et al. Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: the impact of the infection type and the presence of vegetation on survival. Europace 2014;16(10):1496–5. https://doi.org/10.1093/europace/euu147.
[14] Reddy VY, Knops RE, Sperzel J, et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation 2014;129:1466–71. https://doi.org/10.1161/CIRCULATIONAHA.113.069877.
[15] Reddy VY, Exner DV, Cantillon DJ, et al. LEADLESS II Study Investigators.
Percutaneous implantation of an entirely intracardiac leadless pacemaker. N Engl J Med 2015;373:1125–35. https://doi.org/10.1056/NEJMoai1507192.

[16] Reynolds D, Duray GZ, Omar R, et al. Micra Transcatheter Pacing Study Group. A leadless intracardiac transcatheter pacing system. N Engl J Med 2016;374:533–41. https://doi.org/10.1056/NEJMoai1511643.

[17] Duray GZ, Ritter P, El-Chami M, et al. Long-term performance of a transcatheter pacing system: 12-month results from the Micra transcatheter pacing study. Heart Rhythm 2017;14. https://doi.org/10.1016/j.hrthm.2017.01.035. 702–09.

[18] El-Chami MF, Al-Samadi F, Clementy N, et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: a comparison to the investigational study and a transvenous historical control. Heart Rhythm 2018;15(12):1800–7. https://doi.org/10.1016/j.hrthm.2018.08.005.

[19] Kypta A, Blessberger H, Kammler J, et al. Leadless cardiac pacemaker implantation after lead extraction in patients with severe device infection. J Cardiovasc Electrophysiol 2016;27(9):1067–71. https://doi.org/10.1111/jce.13030. indexed in Pubmed: 27296508.